Artiva Biotherapeutics Inc. has implemented a new equity compensation arrangement for select employees, including President and CEO Fred Aslan and COO Jennifer Bush. Under Option for RSU Exchange Agreements, eligible participants were given a one-time opportunity to exchange outstanding stock options with exercise prices above the current market value for restricted stock units (RSUs) granted under the 2024 Equity Incentive Plan. As part of the exchange, Dr. Aslan surrendered options for 869,136 shares and received an equivalent number of RSUs, while Ms. Bush exchanged options for 84,877 shares for RSUs. The RSUs granted in exchange for vested options will vest in installments between August 2026 and February 2027, with full acceleration possible upon certain termination events. RSUs granted for unvested options will vest between August 2026 and February 2029, with partial acceleration in specific circumstances. The RSU grants became effective on December 12, 2025.